Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
CEO: Richard A. Stewart. Company website
Achieve Life Sciences, Inc. (ACHV) trades at $4.95, up 2.91% on the day, as of Sep 20, 2026 15:00 UTC.
Achieve Life Sciences, Inc. has a market capitalisation of $263.54M, calculated from the live ACHV share price and shares outstanding.
ACHV has no meaningful price-to-earnings ratio: Achieve Life Sciences, Inc. lost $1.30 per share over the last twelve months, and a P/E is only defined on positive earnings.
Achieve Life Sciences, Inc. generated revenue of $0.00 over the trailing twelve months.
ACHV has traded between $2.62 and $5.25 over the past 52 weeks, and the last price is 5.7% below that high.
Yes. Achieve Life Sciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
Wall Street analysts rate ACHV Buy, with an average price target of $4.75, 4.0% below the current price.
Achieve Life Sciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in CA .
Richard A. Stewart is the chief executive of Achieve Life Sciences, Inc., which employs 25 people.
QFI Terminal shows ACHV with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ACHV in Terminal See plans